Targeting CD38 with daratumumab monotherapy in multiple myeloma

New England Journal of Medicine

Volumn 373, Issue 13, 2015, Pages 1207-1219

  Lokhorst, H M ^a,b   Plesner, T ^c   Laubach, J P ^f   Nahi, H ^g   Gimsing, P ^d   Hansson, M ^h   Minnema, M C ^a   Lassen, U ^d   Krejcik, J ^c   Palumbo, A ⁱ   Van De Donk, N W C J ^a,b   Ahmadi, T ^j   Khan, I ^k   Uhlar, C M ^j   Wang, J ^k   Sasser, A K ^j   Losic, N ^e   Lisby, S ^e   Basse, L ^e   Brun, N ^e   Richardson, P G ^f   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Genmab   (Denmark)

^f HARVARD MEDICAL SCHOOL   (United States)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD38 ANTIGEN; DARATUMUMAB; IMMUNOMODULATING AGENT; LENALIDOMIDE; M PROTEIN; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC RHINITIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MYELOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG RESISTANCE; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PNEUMONIA; THROMBOCYTOPENIA;

EID: 84942436321     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506348     Document Type: Article

References (24)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-20.
2. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012; 26: 149-57.
3. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol 2014; 7: 97-111.
4. Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol 1998; 161: 4702-8.
5. Deaglio S, Vaisitti T, Billington R, et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 2007; 109: 5390-8.
6. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482-8.
7. Santonocito AM, Consoli U, Bagnato S, et al. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 2004; 28: 469-77.
8. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-8.
9. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015; 7: 311-21.
10. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Presented at the 56th ASH Annual Meeting and Exposition, San Francisco, December 6-9, 2014. abstract.
11. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-5.
12. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.03 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf).
13. Axel AE, McCudden CR, Xie H, Hall BM, Sasser AK. Development of clinical assay to mitigate daratumumab, an IgG1k monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma. Presented at the annual meeting of the American Association for Cancer Research, San Diego, CA, April 5-9, 2014. abstract.
14. McCudden CR, Voorhees PM, Hainsworth SA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem 2010; 56: 1897-9.
15. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-25.
16. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123: 1826-32.
17. Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immunochemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2015; 21: 2802-10.
18. Plesner T, Arkenau H-T, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 2014; 124: 84. abstract. (http://www.bloodjournal.org/content/124/21/84).
19. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014; 20: 4574-83.
20. Martin TG, Hsu K, Strickland SA, Glenn MJ, Mikhael J, Charpentier E. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. J Clin Oncol 2014; 32(15): Suppl: 8532. abstract. (http://meeting.ascopubs.org/cgi/content/abstract/32/15-suppl/8532).
21. Martin TG, Baz R, Benson DM, et al. A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood 2014; 124: 83. abstract. (http://www.bloodjournal.org/content/124/21/83).
22. Richardson PG, Jagannath S, Moreau P, et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2014; 124: 302. abstract. (http://www.bloodjournal.org/content/124/21/302).
23. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552-9.
24. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621-31.